Advance Online
A shot of a woman's legs as she is walking on a path through the woods.
Advance Online

Second SKYRIZI® Indication Approved

FDA approves SKYRIZI® for adults with active PsA

On January 21, 2022 the U.S. Food and Drug Administration (FDA) approved SKYRIZI® (risankizumab-rzaa), an interleukin-23 inhibitor, for the treatment of active psoriatic arthritis (PsA) in adults. [1]

This approval is based on findings from the KEEPsAKE-1 and KEEPsAKE-2 studies, which evaluated safety and efficacy among adult patients with PsA. In both Phase 3 studies, SKYRIZI® met the primary endpoint of ACR20 response at week 24 compared to placebo and demonstrated significant improvements across several other manifestations of PsA, including swollen, tender, and painful joints. [1]

The dosing regimen for SKYRIZI® is similar with to that for patients with moderate-to-severe psoriasis. It is a single 150 mg subcutaneous injection four times a year (after two starter doses at weeks 0 and 4) – and can be administered alone or in combination with DMARDs. [1]

Skyrizi is one of more than a dozen systemic agents approved by the FDA for the treatment of psoriatic disease. For more information on biologics, visit the NPF Biologics resources.

Treatment Options

Learn more about your treatment options, including biologics.

Learn more



Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logoTwill Care logo

Copyright © 1996-2023 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.